Tactile Systems reports Q2 EPS 0c, consensus (5c)

Reports Q2 revenue $68.34M, consensus $65.26M. “We delivered total revenue growth of 15% year-over-year, significant improvements in both our GAAP and non-GAAP profitability and cash flow from operations of more than $13 million in the second quarter,” said Dan Reuvers, president and CEO of Tactile Medical. “Our revenue results were driven primarily by stronger-than-anticipated performance in our lymphedema product line – where we saw improvements in sales team productivity and strong customer adoption following the launch of our Entre(R) Plus system – with modest contributions from sales of our airway clearance products. In addition to our strong operating performance in the second quarter, we continued to make meaningful progress in strengthening our balance sheet.”